Hetero Healthcare Ltd Introduces Hetran, Pioneering a New Generation of Acid Blockers
Hetero Healthcare Ltd, one of India's leading pharmaceutical companies, has launched Vonoprazan, a new-age acid blocker, under the brand name Hetran. It is used for the treatment of gastric acid-related disorders. With this, Hetero becomes the first manufacturer-cum-marketing company to bring this product in India.
Hetran tablets containing Vonoprazan fumarate are available in two dosage strengths - 10mg and 20mg. Vonoprazan a novel potassium-competitive acid blocker (P-CAB), is approved by the DCGI for the treatment of reflux esophagitis, gastroduodenal ulcer, and duodenal ulcer. It can also be combined with antibiotics to eradicate Helicobacter pylori infections.
Unlike available therapies, the onset of action of Vonoprazan starts right from the first dose. Vonoprazan competitively and reversibly blocks the potassium binding site of H+/K+ATPase, allowing a longer duration of action. Additionally, it can be administered independently of food and has minimal drug-drug interactions.
Mr Sandeep Shastri, Executive Director, Hetero Healthcare Ltd said, “With the introduction of Vonoprazan under the brand name Hetran for the first time in India, we are dedicated to providing relief to patients suffering from gastric acid disorders. Numerous studies have shown Vonoprazan's superior efficacy in treating esophagitis and other acid-related disorders, providing rapid and sustained relief compared to conventional therapies”.
He further added, “Proton pump inhibitors fail to adequately control symptoms in up to 40% of patients with reflux diseases. We take pride in bringing this new-age acid blocker, Vonoprazan for the first time in India for the management of acid-related disorders. Hetero Healthcare Ltd is the basic manufacturer of Vonoprazan in the country”.
Hetero Healthcare Ltd, headquartered in Hyderabad, is a pharmaceutical manufacturing company that operates globally in the active pharmaceutical ingredient (API) and generic formulations businesses.
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Hetero Healthcare Ltd.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.